Rizwanullah Ufn, Abifaraj Andrea, Shah Shivani, Kausar Rimsha, Hummad Hytham, Portillo Muñoz Carlos Andres, Hyderi Fardin Akbar, Chi Gomez Lahgi Alejandra, Urbina Raul, Niftalieva Gyullu, Vasquez Zelaya Erick Daniel, Faraj Mustafa
Internal Medicine, Hayatabad Medical Complex Peshawar, Peshawar, PAK.
Medicine and Surgery, Universidad Catolica de Honduras, San Pedro Sula, HND.
Cureus. 2025 May 12;17(5):e83962. doi: 10.7759/cureus.83962. eCollection 2025 May.
Autoimmune hemolytic anemia (AIHA) represents a difficult blood condition that researchers are now positive about treating with rituximab. A systematic review together with a meta-analysis presents findings about rituximab's effectiveness and safety as a treatment against conventional therapy among patients. Data selection occurred through MEDLINE and Embase, along with the Cochrane Library, while the study only accepted research pairing rituximab treatment with traditional AIHA control techniques. The analysis of the study incorporated 10 high-quality research papers to understand patient data, along with ADAMTS13 activity measurements, therapeutic responses, and treatment results. Available results show that rituximab achieves superior outcomes by enhancing remission rates and minimizing plasma exchange requirements together with reduced relapse frequencies during administration through two different protocols at 375 mg/m² weekly for four weeks or 1000 mg in two doses. Results showed that rituximab treatment enabled higher ADAMTS13 activity values, while patients needed fewer plasma exchange procedures when compared to patients who received standard therapy. Steroid use persisted while healthcare providers administered intravenous immunoglobulin and immunosuppressant medications to particular patient groups. Many studies show that rituximab generates prolonged remission benefits and keeps patients safe from adverse effects. Detailed randomized controlled trials need to proceed because treatment designs conflict and patient profiles vary between studies. The review demonstrates that rituximab functions as an effective treatment alternative for AIHA patients who demonstrate positive outcomes and show potential for wider clinical use.
自身免疫性溶血性贫血（AIHA）是一种棘手的血液疾病，不过研究人员现在对使用利妥昔单抗治疗该病持乐观态度。一项系统评价及荟萃分析展示了利妥昔单抗作为一种针对患者的传统疗法的治疗效果及安全性的研究结果。数据选取通过MEDLINE、Embase以及考克兰图书馆进行，而该研究只纳入了将利妥昔单抗治疗与传统AIHA对照技术配对的研究。该研究分析纳入了10篇高质量研究论文，以了解患者数据、ADAMTS13活性测量结果、治疗反应及治疗结果。现有结果表明，利妥昔单抗通过提高缓解率、减少血浆置换需求以及在按照375mg/m²每周一次共四周或分两剂给予每次1000mg的两种不同方案给药期间降低复发频率，从而取得了更好的治疗效果。结果显示，与接受标准治疗的患者相比，利妥昔单抗治疗可使ADAMTS13活性值更高，同时患者需要的血浆置换程序更少。在医疗服务提供者为特定患者群体给予静脉注射免疫球蛋白和免疫抑制药物时，仍会使用类固醇。许多研究表明，利妥昔单抗可带来持久的缓解益处，并使患者免受不良反应影响。由于治疗设计存在冲突且不同研究中的患者特征各异，因此需要开展详细的随机对照试验。该评价表明，对于AIHA患者，利妥昔单抗是一种有效的治疗选择，这些患者显示出良好的治疗效果，并且具有更广泛临床应用的潜力。
